Skip to main content
. 2013 Mar 14;13:115. doi: 10.1186/1471-2407-13-115

Table 2.

Survival analysis of ovarian cancer patients including coexpression of PELP1/ERbeta in the test set (A) and validation set (B)

  Disease-free survival Overall survival
 
 Univariate1
 Multivariate2
 Univariate1
 Multivariate2
 
 P-Value
 P-Value
 HR (95%CI)
 P-Value
 P-Value
 HR (95%CI)
Patients’ age
 0.9
 0.09
 2.1 (0.9-4.9)
 0.9
 0.4
 1.4 (0.6-3.0)
Histological type (serous vs. non-serous)
 0.6
 0.6
 0.8 (0.4-1.8)
 0.4
 0.9
 0.9 (0.5-2.2)
FIGO stage (I vs. II vs. III vs. IV)
 <0.001
 <0.001
 4.4 (1.9-10.1)
 <0.001
 0.007
 3.2 (1.4-7.6)
Residual tumor(no vs. yes)
 <0.001
 0.9
 0.9 (0.4-2.6)
 <0.001
 0.4
 1.6 (0.6-4.3)
ERalpha (negative vs. positive)
 0.8
 -
 -
 0.9
 -
 -
ERbeta (negative vs. positive)
 0.3
 -
 -
 0.2
 -
 -
PELP1 (negative vs. positive)
 0.004
 -
 -
 0.04
 -
 -
PELP1/ERbeta (ERbeta+/PELP1+ vs. others)
 0.03
 0.004
 0.3 (0.1-0.7)
 0.02
 0.005
 0.3 (0.1-0.7)
 
 Disease-free survival
 Overall survival
 
 Univariate1
 Multivariate2
 Univariate1
 Multivariate2
 
 P-Value
 P-Value
 HR (95%CI)
 P-Value
 P-Value
 HR (95%CI)
Patients’ age
 0.09
 0.4
 1.3 (0.7-2.2)
 0.005
 0.04
 2.4 (1.1-5.3)
FIGO stage (I vs. II vs. III vs. IV)
 0.001
 0.02
 1.8 (1.1-3.0)
 0.001
 0.005
 2.5 (1.3-4.7)
Residual tumor (no vs. yes)
 0.003
 0.1
 1.6 (0.9-1.8)
 0.02
 0.3
 1.4 (0.7-2.7)
ERalpha (negative vs. positive)
 0.2
 -
 -
 0.6
 -
 -
ERbeta (negative vs. positive)
 0.7
 -
 -
 0.2
 -
 -
PELP1 (negative vs. positive)
 0.8
 -
 -
 0.9
 -
 -
PELP1/ERbeta (ERbeta+/PELP1+ vs. others) 0.6 0.3 0.7 (0.4-1.3) 0.9 0.3 0.7 (0.3-1.4)

1Log rank test; 2multivariate Cox-regression analysis, HR=Hazard Ratio, 95%CI= 95% Confidence Interval.